Seventy children in The Gambia died after receiving contaminated cough syrup. That single tragedy, devastating on its own, was also a warning. Across Kenya, Ethiopia, Cameroon and Malawi, researchers found that up to 20 percent of sampled cancer medicines moving through both formal and informal supply chains were substandard or falsified. These are not isolated incidents. They are signals of a continent-wide medicines crisis.
The scale is staggering. An estimated one million people across Africa lose their lives to substandard and falsified medicines each year. The World Health Organization reports that 10 to 30 percent of medicines in low- and middle-income countries are substandard or falsified, with Africa accounting for 42 percent of such medicines detected globally. The economic cost runs beyond human suffering: substandard and falsified medicines alone drain more than 200 billion US dollars from economies annually.
Yet the crisis runs deeper than counterfeit drugs. Weak pharmacovigilance systems, poor market surveillance and vulnerable supply chains create conditions where preventable harm becomes routine. Patients experience treatment failure. Healthcare costs climb unnecessarily. Trust in health systems erodes quietly, year by year. The rise of antimicrobial resistance compounds all of this, threatening hard-won progress in infectious disease control across the continent.
What changed: a decision to stop treating these failures as separate problems.
Medicines for Africa will convene the inaugural Africa Patient Safety Summit 2026 in partnership with the African Medicines Agency. The summit brings together regulators, governments, healthcare professionals, pharmaceutical manufacturers, researchers, digital health innovators, patient organisations and development partners on 16 and 17 September 2026 at the Kigali Convention Centre in Rwanda. The gathering takes place under the theme “Advancing Patient Safety Through Collective Action to Prevent Medication-Related Harm.”
The timing is deliberate. The establishment of the African Medicines Agency, accelerating regulatory harmonisation across nations, and rapid advances in digital health have created an opening to strengthen medicines safety that did not previously exist. Those same developments, however, bring emerging risks. Stronger coordination is needed to ensure safety systems keep pace with expanding access to medicines.
Three strategic priorities will shape the summit’s agenda: preventing medication-related harm, strengthening patient-centred regulation, and driving coordinated action across Africa’s medicines ecosystem. By connecting evidence, technical expertise and frontline experience, the gathering aims to move the continent from fragmented efforts toward implementation that protects patients across borders.
Four major outputs are expected to guide that work. A Kigali Declaration on Patient Safety and Medication-Related Harm will establish shared commitments. An Africa Roadmap for Preventing Medication-Related Harm will chart implementation pathways. A Blueprint for Safer Medicines Use and Patient Protection will offer practical guidance for healthcare systems. A Continental Patient Safety Coordination Network (the first of its kind on the continent) will create ongoing mechanisms for collaboration and information sharing.
These outputs are designed to help governments, regulators, healthcare systems and development partners translate political commitment into sustained action. The summit’s underlying premise is straightforward: preventing medication-related harm requires shared responsibility across the entire medicines ecosystem. Medicines must not only reach patients. What reaches them must be safe, effective and worthy of trust.
Whether the Kigali Declaration will carry enough political weight to shift entrenched systems, and how quickly the coordination network can become operational, remains the open question heading into September 2026.